AI assistant
ImageneBio, Inc. — Director's Dealing 2022
Feb 24, 2022
34275_dirs_2022-02-24_6d987cc6-0e3f-471b-bf1e-8c86e06067bb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2022-02-18
Reporting Person: Oliveira Francisco (Principal Accounting Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $4.1493 | 2029-07-10 | Common Stock (30192) | Direct | |
| Stock Option (Right to Buy) | $7.8694 | 2031-02-11 | Common Stock (11182) | Direct | |
| Stock Option (Right to Buy) | $11.45 | 2032-02-01 | Common Stock (30600) | Direct |
Footnotes
F1: 25% of the shares underlying this option vested and became exercisable on May 14, 2020, with the remainder vesting in thirty-six equal monthly installments thereafter.
F2: 25% of the shares underlying this option vested and became exercisable on February 12, 2022, with the remainder vesting in thirty-six equal monthly installments thereafter.
F3: 25% of the shares underlying this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six equal monthly installments thereafter.